Patrick M. Forde

Jan 8, 2025 | brnw.ch | Mark Awad |Patrick M. Forde |Jonathan Spicer

IntroductionPD-(L)1 immune checkpoint inhibitor–based regimens have recently expanded neoadjuvant and adjuvant treatment options for resectable non–small cell lung cancer (NSCLC). Nivolumab, a PD-1 antibody, combined with chemotherapy is now a standard neoadjuvant treatment for eligible patients with resectable NSCLC.

Oct 9, 2024 | nature.com | Ferdinandos Skoulidis |Ana Cobo |Meagan Montesion |Yi Yu |Natalie I. Vokes |Joseph Murray | +44 more

AbstractFor patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of anti-tumour activity and immune-related toxicities, when compared with treatment with PD-(L)1 inhibitors alone. However, there are currently no validated biomarkers to identify which patients will benefit from dual ICB1,2.

Sep 9, 2024 | oncodaily.com | Patrick M. Forde

The International Association for the Study of Lung Cancer (IASLC) is a global, multidisciplinary organization committed to the eradication of all forms of lung cancer. The IASLC unites a diverse group of professionals – including medical, surgical, and radiation oncologists, as well as nurses, basic scientists, pathologists, radiologists, pulmonologists, statisticians, patient advocates, patients, and caregivers in–  its mission to advance the science of lung cancer and enhance patient care.

Sep 9, 2024 | healio.com | Josh Friedman |Mindy Valcarcel |Patrick M. Forde

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Individuals with resectable NSCLC had improved EFS if they received perioperative nivolumab in addition to standard of care therapy. Perioperative nivolumab had a similar safety profile as standard of care.

Aug 1, 2024 | cancernetwork.com | Rahul Gosain |Rohit Gosain |Patrick M. Forde

2 Commerce Drive Cranbury, NJ 08512